Treatment Advances in Heterozygous Familial Hypercholesterolemia

Heterozygous Familial Hypercholesterolemia (HeFH) is a prevalent genetic disorder, which is typically characterized by markedly elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), the presence of tendon xanthomas and corneal arcus, as well as an increased susceptibility to premature atherosclerotic cardiovascular diseases (ASCVD).Extensive research conducted both domestically and internationally has demonstrated that HeFH has a relatively high prevalence. Nevertheless, the awareness and implementation rates of its treatment modalities remain rather low. Currently, commonly adopted treatment strategies encompass lifestyle modifications, the use of statin medications, and PCSK9 inhibitors, among others. As the development of novel lipid-lowering drugs and innovative treatment approaches continues to progress, the range of available treatment options is becoming progressively more diverse. Extensive research conducted both domestically and internationally has demonstrated that HeFH has a relatively high prevalence. Nevertheless, the awareness and implementation rates of its treatment modalities are relatively low. Among the existing treatment regimens, lifestyle interventions, statin drugs, and PCSK9 inhibitors are commonly utilized. As the development of novel lipid-lowering drugs and innovative treatment approaches continues to progress, the range of available treatment options is becoming progressively more diverse. This review aims to explore the existing treatment modalities for heterozygous familial hypercholesterolemia as well as those that can be achieved in the future, with the intention of providing a comprehensive understanding and reference for relevant medical research and clinical practice.